{"id":4142,"date":"2025-03-31T18:11:59","date_gmt":"2025-03-31T18:11:59","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/levofloxacin-txt\/"},"modified":"2025-03-31T18:11:59","modified_gmt":"2025-03-31T18:11:59","slug":"levofloxacin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/levofloxacin-txt\/","title":{"rendered":"Levofloxacin.txt"},"content":{"rendered":"

Levofloxacin <\/h1>\n

CLINICAL USE <\/H3>
\nAntibacterial agent

DOSE IN NORMAL RENAL FUNCTION <\/H3>250\u2013500 mg once or twice a day (varies depending on indication)

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :361.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :30\u201340<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : >85<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.1\u20131.5<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :6\u20138\/35

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Initial dose 250\u2013500 mg then reduce dose by 50%
  • 10 to 20 &nbsp &nbsp : Initial dose 250\u2013500 mg then 125 mg 12\u201324 hourly
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Initial dose 250\u2013500 mg then 125 mg 24\u201348 hourly

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Loading dose: 500 mg then 250 mg every 24 hours.1

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: possibly increased risk of convulsions with NSAIDs\n
  • Anticoagulants: anticoagulant effect of coumarins and phenindione enhanced\n
  • Antimalarials: manufacturer advises avoid concomitant use with artemether and lumefantrine\n
  • Ciclosporin: half-life of ciclosporin increased by 33%; increased risk of nephrotoxicity\n
  • Tacrolimus: may increase tacrolimus concentrationTheophylline: possibly increased risk of convulsions

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV

    Rate of Administration <\/H4>30 minutes per 250 mg

    Comments<\/H4>

    OTHER INFORMATION <\/H4>Dose and frequency depend on indication
    \n","protected":false},"excerpt":{"rendered":"

    Levofloxacin CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4142","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4142"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4142\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}